Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 391

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 391
---
 protocols to support safe and compliant cross -borderoperations. Currently, we do not hold an import permit for biological samples. Instead, we conduct sample imports through our partner and shareholder, CIBIC, who holds the necessary permits and oversees compliance with import regulations. As we continue expanding our operations in Latin America, we aim to develop our own import capabilities in the near future to support our growth. Privacy and Security Regulation We believe that Heritas Argentina, our main operating subsidiary, is fully compliant with Argentina’s national data protection law, Law 25,326, which provides a framework for the protection of personal data, including sensitive health -relatedinformation. This legislation establishes the principles for the lawful processing of personal data and is 195 particularly pertinent to health -relatedinformation. It guarantees that personal, health, and credit data are safeguarded and that such data cannot be utilized without explicit consent. We ensure that all our products and services offered adhere strictly to these principles, safeguarding our clients’ data and upholding their right to data privacy and protection. As we enter or expand our business to other international jurisdictions, there may be several privacy and data protection laws that apply to our business. These laws are usually triggered by our physical location in the jurisdiction, data processing activities that take place in the jurisdiction, and/or the processing of personal information about individuals located in that jurisdiction. In response, we are committed to compliance with the most stringent standards applicable, ensuring robust protection of our customers’ privacy and the security of their data across all jurisdictions. This commitment is integral to our operational ethos and is critical to maintaining the trust and confidence of our customers worldwide. Clinical Trials To validate the sensitivity and specificity of our genomic tests, we conducted clinical studies under GCP guidelines to ensure scientific credibility and data reliability. Adhering to GCP standards safeguards participant rights, safety, and data confidentiality, supporting regulatory approval by demonstrating rigorous, ethical research methodologies. This approach facilitates the integration of genomic diagnostics into clinical practice while building trust among patients, healthcare providers, and regulatory bodies, thereby accelerating the acceptance and integration of genomic diagnostics into clinical practice. Each country has different regulations about how to generate data and validate the accuracy of a genetic diagnostic test. By applying the highest international standards in our clinical studies, we strive to ensure that we can use the information irrespective of borders. If necessary, we gather local data to validate genomic backgrounds and environmental conditions. Cardiovascular Disease Polygenic Risk Score (PRS) Study A cross -sectionalstudy was conducted from June 2022 to October 2023